What's the most recent regulatory action in Partial Epilepsy Treatment Adjunct?

Most recent: Keppra — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/partial-epilepsy-treatment-adjunct.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Partial Epilepsy Treatment Adjunct — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Partial Epilepsy Treatment Adjunct (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Partial Epilepsy Treatment Adjunct, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Keppra	levetiracetam	Generic (originally UCB Pharma)	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
Neurontin	gabapentin	Generic (originally Parke-Davis/Pfizer)	Gabapentinoid (anticonvulsant/neuropathic pain agent)	Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor	1993-12-30
Tranxene	clorazepate	Ajenat Pharms	Benzodiazepine	GABA-A receptor alpha-1/beta-2/gamma-2	1972-01-01
gabapentine	gabapentine	Dominik Irnich		Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor
Keppra	Keppra	Masonic Cancer Center, University of Minnesota		Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A
Vimpat	lacosamide	UCB		Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12
Zonegran	Zonegran	Dr. Reddy's Laboratories Limited		Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12
Retigabine	Retigabine	Bausch Health Americas, Inc.		Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3, Potassium voltage-gated channel subfamily KQT member 4

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-08 — Keppra · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Ajenat Pharms · 1 drug in Partial Epilepsy Treatment Adjunct
Bausch Health Americas, Inc. · 1 drug in Partial Epilepsy Treatment Adjunct
Dominik Irnich · 1 drug in Partial Epilepsy Treatment Adjunct
Dr. Reddy's Laboratories Limited · 1 drug in Partial Epilepsy Treatment Adjunct
Generic (originally Parke-Davis/Pfizer) · 1 drug in Partial Epilepsy Treatment Adjunct
Generic (originally UCB Pharma) · 1 drug in Partial Epilepsy Treatment Adjunct
Masonic Cancer Center, University of Minnesota · 1 drug in Partial Epilepsy Treatment Adjunct
UCB · 1 drug in Partial Epilepsy Treatment Adjunct

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Partial Epilepsy Treatment Adjunct:

Cite this brief

Drug Landscape (2026). Partial Epilepsy Treatment Adjunct — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/partial-epilepsy-treatment-adjunct. Accessed 2026-06-10.

Partial Epilepsy Treatment Adjunct full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing